EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, VOR: Vor Biopharma Inc

24 Nov 25 14:38
LAST:

8.370

CHANGE:
 0.92		OPEN:
7.910		HIGH:
8.770		ASK:
0.000		VOLUME:
600.9K
CHG(%):
12.35		PREV:
7.450		LOW:
7.810		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Nov 257.9108.7707.8108.370600.9K
21 Nov 256.7707.6006.6907.450735.6K
20 Nov 257.8208.1606.5006.8601.09M
19 Nov 258.9009.2107.7607.820794.4K
18 Nov 259.95010.1509.0009.1201.01M
17 Nov 2510.00010.2509.68510.020778.7K
14 Nov 259.50010.3509.50010.010523.6K
13 Nov 259.96010.4509.5009.750869.2K
12 Nov 2510.00010.5009.72010.0601.33M
11 Nov 259.51010.2109.0009.8409.19M

PROFILE

Name:Vor Biopharma Inc
About:Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:100 Cambridgepark Drive, Cambridge, MA, United States, 02140
Website:https://www.vorbio.com
CUSIP:929033108
CIK:0001817229
ISIN:US9290331084
FIGI:BBG00NBJRDT6

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-0.66 
Forward P/E:-19.26 
Price to Book:-0.09 
Return on Assets:-1.21 
Return on Equity:-1.21 
EPS Ratio:-273.60 
Shares:6.85M 
Market Cap:57.37M 

TECHNICAL INDICATORS

MA5:7.935.5%
MA10:8.936.7%
MA20:15.5685.9%
MA50:23.81184.4%
MA100:12.9654.8%
MA200:6.8122.9%
STO9:42.31
STO14:10.37 
RSI14:14.49 
WPR14:-89.04 
MTM14:-12.51
ROC14:-0.60 
ATR:1.88 
Week High:10.2522.5%
Week Low:6.5028.8%
Month High:28.66242.4%
Month Low:6.5022.9%
Year High:49.95496.8%
Year Low:0.136,284.4%

RECENT SPLITS

Date Ratio
19 Sep 20251-20